Omeros (OMER) Other Accumulated Expenses (2011 - 2026)
Omeros recorded quarterly Other Accumulated Expenses of $617000.0 in Q1 2026, up 63.23% quarter-over-quarter from $378000.0 in Q4 2025, and up 10.18% year-over-year from $560000.0 in Q1 2025.
Omeros' Other Accumulated Expenses history runs 12 years deep, the most recent figure standing at $617000.0 for Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 10.18% year-over-year to $617000.0; the TTM figure through Mar 2026 stood at $617000.0 (up 10.18% YoY), while the FY2025 annual figure was $378000.0, up 92.86% from the prior year.
- Other Accumulated Expenses came in at $617000.0 for Q1 2026 at Omeros, up from $378000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $30.6 million in Q4 2022 to a low of $196000.0 in Q4 2024.
- A 5-year average of $7.0 million and a median of $674000.0 in 2022 frame the typical range for Other Accumulated Expenses.
- Across the five-year window, Other Accumulated Expenses plunged 98.97% in 2023 and jumped 4158.17% in 2024, its largest moves.
- Omeros' Other Accumulated Expenses stood at $30.6 million in 2022, then slumped by 98.97% to $316000.0 in 2023, then tumbled by 37.97% to $196000.0 in 2024, then jumped by 92.86% to $378000.0 in 2025, then soared by 63.23% to $617000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $617000.0, $378000.0, and $272000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 617,000.00 |
| Dec 31, 2025 | 378,000.00 |
| Sep 30, 2025 | 272,000.00 |
| Jun 30, 2025 | 335,000.00 |
| Mar 31, 2025 | 560,000.00 |
| Dec 31, 2024 | 196,000.00 |
| Sep 30, 2024 | 23.25 Mn |
| Jun 30, 2024 | 27.97 Mn |
| Mar 31, 2024 | 28.40 Mn |
| Dec 31, 2023 | 316,000.00 |
| Sep 30, 2023 | 858,000.00 |
| Jun 30, 2023 | 847,000.00 |
| Mar 31, 2023 | 667,000.00 |
| Dec 31, 2022 | 30.55 Mn |
| Sep 30, 2022 | 674,000.00 |
| Jun 30, 2022 | 1.40 Mn |
| Mar 31, 2022 | 1.41 Mn |
| Dec 31, 2021 | 1.68 Mn |
| Sep 30, 2021 | 746,000.00 |
| Jun 30, 2021 | 484,000.00 |
| Mar 31, 2021 | 738,000.00 |
| Dec 31, 2020 | 810,000.00 |
| Sep 30, 2020 | 822,000.00 |
| Jun 30, 2020 | 881,000.00 |
| Mar 31, 2020 | 778,000.00 |
| Dec 31, 2019 | 872,000.00 |
| Sep 30, 2019 | 859,000.00 |
| Jun 30, 2019 | 801,000.00 |
| Dec 31, 2018 | 1.22 Mn |
| Mar 31, 2013 | 1.56 Mn |
| Dec 31, 2012 | 687,000.00 |
| Sep 30, 2012 | 3.95 Mn |
| Jun 30, 2012 | 224,000.00 |
| Dec 31, 2011 | 722,000.00 |